Insmed Price Target Raised to $100.00/Share From $85.00 by Truist Securities
Truist Financial Maintains Insmed(INSM.US) With Buy Rating
Insmed Analyst Ratings
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $75 to $98
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Verona Pharma (VRNA) and Hims & Hers Health (HIMS)
TD Cowen Sticks to Its Buy Rating for Insmed (INSM)
Brensocatib Shows Broad Efficacy in NCFB Subpopulations, Justifying Buy Rating for Insmed
Insmed Is Maintained at Overweight by JP Morgan
Insmed Analyst Ratings
Evercore Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $75
Barclays Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $90
Barclays Sticks to Their Buy Rating for Insmed (INSM)
Stifel Maintains Insmed(INSM.US) With Buy Rating
Insmed Maintains Competitive Edge Amid Lackluster Trial Results for Rival Drug BI 1291583
Insmed Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target
H.C. Wainwright Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $90
Insmed's Brensocatib Poised for Market Leadership: A Buy Rating Amidst Unthreatening Competition
Buy Rating Affirmed for Insmed on Breakthrough Trials and Market Expansion Opportunities
Truist Financial Reaffirms Their Buy Rating on Insmed (INSM)